Trial Profile
An Open-Label, Dose Escalation Study of the Safety and Tolerability of 20089 (Triamcinolone Acetonide Intravitreal Injection) in the Treatment of Patients with Cystoid Macular Edema Associated with Retinal Vein Occlusion or Cataract Surgery
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Triamcinolone (Primary)
- Indications Retinal oedema
- Focus Adverse reactions
- Sponsors EyePoint Pharmaceuticals; Icon Bioscience
- 28 Mar 2018 According to an EyePoint Pharmaceuticals media release, pSivida Corp. acquired Icon Bioscience and subsequently changed its name to EyePoint Pharmaceuticals.
- 24 May 2016 New trial record